CYP1B1 polymorphisms and K-ras mutations in patients with pancreatic ductal adenocarcinoma

Marta Crous-Bou, Immaculata De Vivo, Miquel Porta, José A. Pumarega, Tomàs López, Joan Alguacil, Eva Morales, Núria Malats, Juli Rifà, David J. Hunter, Francisco X. Real

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


The frequency of CYP1B1 polymorphisms in pancreatic cancer has never been reported. There is also no evidence on the relationship between CYP1B1 variants and mutations in ras genes (K-, H- or N-ras) in any human neoplasm. We analyzed the following CYP1B1 polymorphisms in 129 incident cases of pancreatic ductal adenocarcinoma (PDA): the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453). The calculated frequencies for the m1 Val and m2 Asn alleles were 0.45 and 0.68, respectively. CYP1B1 genotypes were out of Hardy-Weinberg equilibrium; this was largely due to K-ras mutated PDA cases. The Val/Val genotype was over five times more frequent in PDA cases with a K-ras mutation than in wild-type cases (OR = 5.25; P = 0.121). In PDA, polymorphisms in CYP1B1 might be related with K-ras activation pathways. © 2008 Springer Science+Business Media, LLC.
Original languageEnglish
Pages (from-to)1417-1421
JournalDigestive Diseases and Sciences
Issue number5
Publication statusPublished - 1 Jan 2008


  • CYP1B1 polymorphisms
  • K-ras oncogene
  • Pancreatic neoplasms
  • Ras genes


Dive into the research topics of 'CYP1B1 polymorphisms and K-ras mutations in patients with pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this